Anatomic Changes Can Be Seen With MRI-Linac for Glioblastoma Patients
By Elana Gotkine HealthDay Reporter
FRIDAY, Oct. 11, 2024 -- For patients with glioblastoma imaged daily with magnetic resonance imaging (MRI)-linear accelerator (linac) throughout the chemoradiation therapy course, anatomic changes can be detected, according to a study published online Sept. 30 in the International Journal of Radiology Oncology - Biology - Physics.
Kaylie Cullison, Ph.D., from the University of Miami Miller School of Medicine, and colleagues examined dynamics of daily glioblastoma evolution during chemoradiation therapy among 36 patients with glioblastoma. Tumor or edema (lesion) and resection cavity dynamics were analyzed throughout treatment on 0.35T MRI-linac and at three timepoints (T) with and without contrast (C) on standalone high-field MRI. Of the patients, eight, 12, and 16 had cavity only, lesions only, and cavity and lesions, respectively.
The researchers found that on MRI-linac scans, 64 and 46 percent of the patients had lesion growth and cavity shrinkage during treatment, respectively. The average MRI-linac migration distance was 1.3 and 0.6 cm for lesion and cavity, respectively. There was a strong correlation observed for standalone versus MRI-linac volumes (R2 values of 0.991, 0.972, and 0.973 for T2 versus MRI-linac cavity, T1 + C versus MRI-linac cavity, and T2 versus MRI-linac lesion), respectively. A moderate correlation was seen between T1 + C and MRI-linac lesions (R2, 0.609). In patients with all available scans, from pretreatment to posttreatment, T1 + C and MRI-linac lesions changed together in 74 percent of patients (shrank, grew, and did not change in six, 12, and eight, respectively). Nine patients (26 percent) had growth on MRI-linac and shrinkage on T1 + C.
"Our study shows that these daily scans can serve as an early warning sign for potential tumor growth," Cullison said in a statement.
Several authors disclosed ties to ViewRay.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Study Offers Comprehensive Evaluation of Survival Parameters for Pediatric CNS Tumors
MONDAY, Aug. 4, 2025 -- The survival probabilities of pediatric central nervous system (CNS) tumors in Europe have been explored in a study published in the August issue of The...
Optical Coherence Tomography Feasible for Imaging Inner Ear
WEDNESDAY, July 30, 2025 -- Imaging the inner ear during surgical procedures is feasible and allows detection of endolymphatic hydrops, according to a study published online July...
Low Rates of Isolated Locoregional Recurrence Seen in Young Women With Breast Cancer
TUESDAY, July 29, 2025 -- For women diagnosed with breast cancer at age 40 years or younger, the risk for isolated locoregional recurrence (LRR) is relatively low, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.